Subcutaneous immunisation with zymosan generates mucosal IgA-eliciting memory and protects mice from heterologous influenza virus infection
International Immunology · 2023
DOI: 10.1093/intimm/dxad013 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunology, 2023. Verfasst von Yoshihito Nihei und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Juntendo University Faculty of Medicine, Bunkyo-ku, Tokyo 113-8421, Japan. Hauptthemen laut MEDLINE: Influenza, Human, Influenza Vaccines, Orthomyxoviridae Infections, Communicable Diseases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Immunoglobulin A (IgA) is the most abundant isotype of antibodies and provides a first line of defense at the mucosa against pathogens invading the host. It has been widely accepted that the mucosal IgA response provided by vaccination requires mucosal inoculation, and intranasal inoculation has been proposed for vaccines against influenza virus. Considering the difficulty of intranasal vaccination in infants or elderly people, however, parenteral vaccination that provides the mucosal IgA response is desirable. Here, we demonstrate that subcutaneous immunisation with zymosan, a yeast cell wall constituent known to be recognised by Dectin-1 and TLR2, potentiates the production of antigen-specific IgA antibodies in the sera and airway mucosa upon intranasal antigen challenge. We confirmed that the antigen-specific IgA-secreting cells accumulated in the lung and nasal-associated lymphoid tissues after the antigen challenge. Such an adjuvant effect of zymosan in the primary immunisation for the IgA response depended on Dectin-1 signalling, but not on TLR2. The IgA response to the antigen challenge required both antigen-specific memory B and T cells, and the generation of memory T cells, but not memory B cells, depended on zymosan as an adjuvant. Finally, we demonstrated that subcutaneous inoculation of inactivated influenza virus with zymosan, but not with alum, mostly protected the mice from infection with a lethal dose of a heterologous virus strain. These data suggest that zymosan is a possible adjuvant for parenteral immunisation that generates memory IgA responses to respiratory viruses such as influenza virus.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Juntendo University Faculty of Medicine, Bunkyo-ku, Tokyo 113-8421, Japan.
- Division of Cancer Cell Biology, Research Institute for Biomedical Sciences (RIBS), Tokyo University of Science, Noda, Chiba 278-0022, Japan.
- Laboratory for Cytokine Regulation, Center for Integrative Medical Science, RIKEN Yokohama Institute, Yokohama, Kanagawa 230-0045, Japan.
- Division of Molecular Pathology, RIBS, Tokyo University of Science, Noda, Chiba 278-0022, Japan.
ORCID-Profile: Daisuke Kitamura
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Nihei, Y., Higashiyama, M., Miyauchi, K., Haniuda, K., Suzuki, Y., Kubo, M., & Kitamura, D. (2023). Subcutaneous immunisation with zymosan generates mucosal IgA-eliciting memory and protects mice from heterologous influenza virus infection. International Immunology. https://doi.org/10.1093/intimm/dxad013
Vancouver
Nihei Y, Higashiyama M, Miyauchi K, Haniuda K, Suzuki Y, Kubo M, et al. Subcutaneous immunisation with zymosan generates mucosal IgA-eliciting memory and protects mice from heterologous influenza virus infection. International Immunology. 2023. doi:10.1093/intimm/dxad013
BibTeX
@article{Nihei2023,
author = {Nihei, Yoshihito and Higashiyama, Mizuki and Miyauchi, Kosuke and Haniuda, Kei and Suzuki, Yusuke and Kubo, Masato and Kitamura, Daisuke},
title = {Subcutaneous immunisation with zymosan generates mucosal IgA-eliciting memory and protects mice from heterologous influenza virus infection},
journal = {International Immunology},
year = {2023},
doi = {10.1093/intimm/dxad013}
}
EUVIMED